[H-3] D/L-Rosiglitazone

Rosiglitazone is an oral prescription medication that belongs to a class of drugs called thiazolidinediones (often referred to as "glitazones"). It is used to help manage blood sugar levels in adults with type 2 diabetes.  Instead of prompting the pancreas to produce more insulin, rosiglitazone works by making the body's cells more sensitive to the insulin that is already present. It binds to specific receptors in fat, muscle, and liver cells, which helps these tissues take up glucose from the bloodstream more effectively and lowers overall blood sugar levels

Rosiglitazone acts as a high-affinity full agonist at PPAR-γ nuclear receptors, predominantly expressed in adipose tissue. Upon binding, it induces a conformational change that promotes heterodimerization with retinoid X receptors (RXR), which then binds to specific DNA response elements to alter the transcription of genes regulating glucose and lipid metabolism.

The primary clinical benefit of rosiglitazone is durable glycemic control, achieved by enhancing peripheral insulin sensitivity without triggering hypoglycemia. However, these benefits are offset by significant clinical risks, including fluid retention leading to congestive heart failure, progressive weight gain, and an increased incidence of bone fractures (particularly in women).

Rosiglitazone improves glycemic control by targeting peripheral tissue responsiveness rather than pancreatic beta-cell secretion. By activating PPAR-γ, it upregulates GLUT4 glucose transporters and reduces circulating free fatty acids, thereby facilitating increased glucose uptake in adipose tissue and skeletal muscle while reducing hepatic glucose output.

While both belong to the thiazolidinedione class, rosiglitazone is a selective PPAR-γ agonist, whereas pioglitazone acts as a dual agonist at both PPAR-γ and PPAR-α. As a result of its PPAR-α activity, pioglitazone exerts a more favorable lipid profile (reducing triglycerides and raising HDL), whereas rosiglitazone tends to increase total cholesterol and LDL levels.

Yes, following a 2007 meta-analysis suggesting an increased risk of myocardial infarction, the FDA initially placed severe prescribing restrictions on rosiglitazone. However, after a thorough 2013 readjudication of the randomized RECORD trial found no elevated risk of heart attack or death compared to standard diabetes drugs, the FDA removed these prescribing restrictions

Rosiglitazone is approved both as a monotherapy alongside diet and exercise and in dual or triple combination regimens with other oral antidiabetic agents like metformin or sulfonylureas. However, its combination with insulin is generally avoided or heavily restricted due to a substantially heightened risk of severe fluid retention and heart failure.

Common side effects of rosiglitazone include peripheral edema, dose-dependent weight gain, mild anemia (secondary to fluid retention and hemodilution), and upper respiratory tract infections. Long-term use is also associated with an elevated risk of bone fractures and a worsening or precipitation of congestive heart failure.